Christopher Cleary – Member of the Board of Directors at Cirtec Medical

Christopher Cleary has been appointed to the Board of Directors at Cirtec Medical, bringing over 30 years of highly specialized experience in corporate development, mergers and acquisitions, venture investing, and strategic growth within the medical technology and healthcare sectors. Cleary currently serves as CEO of Biomergence Capital, a role in which he has focused on guiding emerging companies through operational scaling, strategic investments, and market expansion initiatives. Previously, he led global acquisition and investment strategies at Medtronic, where he executed over 35 acquisitions and numerous venture investments, significantly enhancing the company’s market position and product portfolio.

Among his most notable achievements are Medtronic’s $50 billion acquisition of Covidien in 2014, which was transformative for the company, and the $6 billion divestiture of Covidien’s medical supply assets to Cardinal Health, showcasing his expertise in complex, high-value transactions. At Cirtec Medical, Cleary’s role will encompass guiding strategic mergers and acquisitions, advising on commercial and product portfolio decisions, supporting global market expansion, and leveraging his deep industry network to enhance Cirtec’s innovative capabilities. His extensive experience in deal-making, corporate growth, and leadership aligns with Cirtec’s mission to deliver high-quality medical device solutions and strengthen its position as a trusted partner for global healthcare providers. Cleary’s appointment reflects Cirtec Medical’s commitment to strategic governance, operational excellence, and long-term innovation in the medical device industry.